CONTEXT THERAPEUTICS INC (CNTX)
Health Care · Biotechnology · NASDAQ
Context Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of T cell engaging bispecific antibodies to treat solid tumors.
What CONTEXT THERAPEUTICS INC does
Context Therapeutics is a clinical-stage biopharmaceutical company focused on developing T cell engaging (TCE) bispecific antibodies to treat solid tumors. Its pipeline features candidates designed to redirect immune-mediated lysis toward specific tumor targets, with current lead programs targeting CLDN6 and Nectin-4. The company prioritizes developing novel therapeutic candidates through clinical-stage trials, either independently or through strategic partnerships.
Recent developments
In August 2026, the company announced a strategic decision to discontinue internal development of its CT-95 program to focus capital and resources on the CTIM-76 and CT-202 programs. CTIM-76 received FDA Fast Track designation in April 2026 for the treatment of platinum-resistant ovarian cancer.
From CONTEXT THERAPEUTICS INC's filing of 2026-08-05.
Themes: oncology, T cell engagers, bispecific antibodies, solid tumors, CLDN6 targeting, Nectin-4 targeting
Fundamentals
- Price$0.299 as of 2026-10-08 close
- Market cap$27M as of 2026-08-03 (share count; price 2026-10-08)
- 1-year return-73.8% 2025-10-08 close $1.14 → 2026-10-08 close $0.299
- P/En/a negative earnings
- ROE-59.7% FY2025, SEC XBRL
- Debt / equity0.00 as of 2026-09-03
- Beta0.90 as of 2026-09-03
- Last reported earnings2023-03-22 most recent in our data — SEC EDGAR Form 8-K (Item 2.02); no newer announcement filed
How CNTX compares in its sector
- return on equitybottom 25% 510 covered Health Care peers, as of 2026-09-03
- free cash flow (absolute dollars, latest fiscal year)middle range 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How CONTEXT THERAPEUTICS INC looks technically
CONTEXT THERAPEUTICS INC (CNTX) is trading 80.6% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed below its 200-day average about 65 trading days ago — a "death cross", a bearish long-term signal. A strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 38, with sellers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 33, neither overbought (above 70) nor oversold (below 30). It just made a new 20-day low, breaking below its recent trading range. It is 1.2% above its 52-week low (its lowest price of the past year).
Trend
8
| Distance from the 200-day | it is trading 80.6% below its 200-day average, the long-term trend line — a long-term downtrend | -80.6% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $0.4208 | $0.4208 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $1.54 | $1.54 |
| Swing structure | each recent peak has been lower than the one before it and each dip deeper — the pattern chart-watchers call a downtrend, which describes where price has already been and not where it goes next | lower highs and lower lows |
| Last swing turn | its last significant turn was a swing low 8 calendar days ago — the swings before that are what the structure reading is measured on | 8 sessions |
| Wave structure | its recent swings can be read as a completed five-part downward sequence — the pattern Elliott-wave chartists call an impulse — which on that reading would now be due a pullback rather than more of the same; the labelling fails if price closes below 0.297. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible five-wave downward sequence, complete (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 65 trading days ago — a "death cross", a bearish long-term signal | 65 sessions |
| Trend strength (14-day ADX) | a strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 38, with sellers in control | 37.5 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 33, neither overbought (above 70) nor oversold (below 30) | 33.0 |
|---|---|---|
| Position in its 14-day range | it is trading right at the bottom of its 14-day range ($0.2954 to $0.3967) — its "stochastic" reading is 4 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 3.6 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in positive territory (momentum leaning bullish) | 25 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $3.62 | $3.62 |
|---|---|---|
| From the 52-week high | it is 91.7% below its 52-week high (its highest price of the past year) | -91.7% |
| Above the 52-week low | it is 1.2% above its 52-week low (its lowest price of the past year) | +1.2% |
| Below the 52-week high | it is 91.7% below its highest point of the past year | 91.7% |
| Since a 20-day breakout | it just made a new 20-day low, breaking below its recent trading range | 1 session |
| Since a 55-day breakout | it just made a new 55-day low, breaking below its recent trading range | 1 session |
| All-time high | its highest closing price on record is $3.62 (set on 2026-03-16) | $3.62 |
| Given back of the 52-week move | over the past year its closes ranged ($0.299 to $3.36), and it has recovered essentially none of its fall from last year’s high — 0% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $2.19 to $2.29. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 0.0% |
| From the all-time high | it is 91.7% below its all-time high | -91.7% |
| Nearest price level | it is trading 83.0% below a resistance level at $0.5473 — a price it turned at three times since 2025-04-01, most recently on 2026-08-21. Since 2024-10-08 it has 0 such levels below the current price and 12 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +83.0% |
| All-time low | its lowest closing price on record is $0.2954 (set on 2026-10-08) | $0.2954 |
| Above the all-time low | it is 1.2% above its all-time low | +1.2% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 52nd percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.0291 between its high and its low — about 9.7% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.0291 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $0.29 and $0.4 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $0.29 – $0.34 – $0.4 |
| Typical daily range (% of price) | its price moves about 9.7% in a typical session — among the most volatile in the catalog. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 9.7% |
| Stretch from the 200-day average | it is trading 42.8 daily ranges below its 200-day average price (80.6% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 42.8 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.76× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | not available for this company yet | n/a |
Candlestick patterns
1
| Since a bullish engulfing | 3 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 3 sessions ago |
|---|
Price gaps
3
| Gap at the open | it opened on 2026-10-08 0.7% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | -0.7% |
|---|---|---|
| Open gap | it gapped 27.1% below the previous close 44 sessions ago and has not traded back through the level it left behind at 0.69 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | -27.1% |
| Gap filled | a 3.0% gap up opened on 2026-10-01 has been "filled" 5 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 5 sessions ago |
Price streaks
1
| Closing streak | it has closed lower 3 sessions in a row, a -11.28% move over the run — an unbroken run of down days, which describes what has already happened and says nothing about the next session | 3 sessions down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 21.5 percentage points (the stock lost 20.5% while the market gained 1.0%) | -21.5% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 53.7 percentage points (the stock lost 49.8% while the market gained 3.8%) | -53.7% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 106.4 percentage points (the stock lost 89.0% while the market gained 17.5%) | -106.4% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 88.8 percentage points (the stock lost 73.8% while the market gained 15.0%) | -88.8% |
Signal agreement
2
| Bullish technical signals | 2 of the 9 technical signals we can compute for it are currently in a bullish state: MACD momentum is positive, near the bottom of its 14-day range (oversold) — these describe past price behaviour, not a forecast | 2 of 9 |
|---|---|---|
| Bearish technical signals | 6 of the 9 technical signals we can compute for it are currently in a bearish state: a "death cross" — its 50-day average is below its 200-day, trading below its 200-day average, a fresh 20-day low, a strong downtrend, with sellers in control, lagging the market over 6 months, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 6 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 39% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-01 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is thick, spanning 13.6% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | -39.0% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 76% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $1.23 — a volume-weighted average of daily closes over 190 sessions, not a true tick-by-tick VWAP. | -75.6% |
|---|---|---|
| Vs the average paid since it last reported | the price is 31% below the average price paid since it last reported on 2026-08-05 (its 10-Q), so the typical buyer over that stretch is under water. That average is $0.4321 — a volume-weighted average of daily closes over 46 sessions, not a true tick-by-tick VWAP. | -30.8% |
Price levels it has turned at before
CNTX last closed at $0.299 on 2026-10-08. Since 2024-10-08 it has turned at 0 prices below its last close and 12 above; the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $0.5473 | Resistance | 83.0% above the last close | turned there three times · 2025-04-01 to 2026-08-21 |
| $0.56 | Resistance | 87.3% above the last close | turned there twice · 2026-07-09 to 2026-07-24 |
| $0.699 | Resistance | 133.8% above the last close | turned there three times · 2025-06-30 to 2026-08-05 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now complete.
This labelling fails — stops being a possible reading at all — if it closes below $0.297.
It is the only labelling that fits these swings, though its proportions are not the textbook ones. It was chosen from 3 labellings that survived the rules, counting shorter readings of the same bars.
This reading has stood for 2 trading days, since 2026-10-07.
Read from daily closes as of 2026-10-08.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Near the 52-week low · Pulled back from the 12-month high · Broke down to a new 20-day low · Near the all-time low · lagging the market | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low
Based on daily closing prices as of 2026-10-08. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Mean price target$4.03 range $2.00 – $5.00; median $4.50
Analyst estimates, as of 2026-10-08. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for CNTX
- Consensus EPS estimate-$0.1075 next reporting period, as of 2026-10-08
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Significant operating losses and reliance on continued capital raising to fund research and development.","Potential delisting from the Nasdaq Capital Market due to failure to meet the minimum bid price requirement.","Dependence on intellectual property rights for clinical candidates, including risks related to potential third-party infringement claims."]
What changed in the latest 10-Q
AI-assisted comparison of CNTX's 10-Q filed 2026-08-05 against the prior one filed 2026-05-06.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing (2026-08-05) adds that on August 5, 2026, the company announced a portfolio prioritization and capital allocation strategy, discontinuing internal development of CT-95 and focusing development efforts on CTIM-76 and CT-202.
- Newer filing (2026-08-05) adds that CTIM-76 is advancing into every-three-week (Q3W) dosing in patients with platinum-resistant ovarian cancer (PROC).
- Newer filing (2026-08-05) adds a plan to evaluate CTIM-76 using a Q3W dosing regimen in less heavily pretreated PROC patients in the second half of 2026 to further characterize its clinical profile.
- Newer filing (2026-08-05) adds an expectation to share initial Phase 1a data for the CTIM-76 Q3W trial in the second quarter of 2027.
- Newer filing (2026-08-05) adds an anticipated initiation of a Phase 1b dose expansion trial for CTIM-76 in the first quarter of 2027.
- Newer filing (2026-08-05) adds that the first patient in the CT-202 Phase 1 clinical trial is expected to be dosed in the third quarter of 2026.
- Newer filing (2026-08-05) adds an expectation to share initial Phase 1a data from the CT-202 trial in the second half of 2027.
- Newer filing (2026-08-05) adds that the company expects to wind down the CT-95 Phase 1 trial promptly in connection with its decision to discontinue internal development of CT-95.
- Newer filing (2026-08-05) states net loss was $23.2 million for the six months ended June 30, 2026, and accumulated deficit was $154.1 million as of June 30, 2026.
- Newer filing (2026-08-05) refers to the amendment as the "Integral Second Amendment" and to the agreement as the "Integral License Agreement" (as amended).
- Newer filing (2026-08-05) describes the licensed subject matter as "CLDN6 bispecific antibodies" instead of "CLDN6 bsAb".
- Removed:
- Older filing (2026-05-06) includes CT-95 as part of the innovative portfolio of TCE bispecific therapeutics.
- Older filing (2026-05-06) states that IND-enabling studies on CTIM-76 have been completed.
- Older filing (2026-05-06) states an expectation to share Phase 1a interim data for the CTIM-76 trial in June 2026.
- Older filing (2026-05-06) describes MSLN as a membrane protein overexpressed in approximately 30% of cancers and includes an expectation to share Phase 1a interim data for the CT-95 trial in September 2026.
- Older filing (2026-05-06) states net loss was $8.7 million for the three months ended March 31, 2026, and accumulated deficit was $139.6 million as of March 31, 2026.
- Older filing (2026-05-06) includes a section titled "CT-95: Link Purchase Agreement" describing the July 9, 2024 asset purchase agreement with Link, including a one-time payment of $3.75 million.
- Older filing (2026-05-06) includes a section titled "CT-202: BioAtla License Agreement" (heading present but content not included in the older text).
- Older filing (2026-05-06) uses "Second Amendment" and "Research Collaboration and License Agreement" terminology instead of "Integral Second Amendment".
- Reworded:
- Newer filing (2026-08-05) changes the expectation from 'share Phase 1a interim data for the CTIM-76 trial in June 2026' (older) to 'presented interim Phase 1a clinical data for our CTIM-76 trial in June 2026' (newer).
- Newer filing (2026-08-05) changes the CT-202 first patient dosing language from 'We expect to dose the first patient in our CT-202 Phase 1 clinical trial in the third quarter of 2026' (older) to 'The first patient in our Phase 1 clinical trial evaluating CT-202 in patients with Nectin-4-positive urothelial, colorectal, and triple-negative breast cancers is expected to be dosed in the third quarter of 2026' (newer).
- Newer filing (2026-08-05) changes the milestone list format from a single comma-separated list (older) to an enumerated list with Roman numerals (newer).
- Newer filing (2026-08-05) changes 'obtain a license to such patent' (older) to 'obtain a license to such patents' (newer).
- Notes:
- The newer filing text ends mid-sentence after 'annual net sales of' in the Integral Molecular section, so changes after that point cannot be assessed.
- The older filing includes a heading for 'CT-202: BioAtla License Agreement' but no section content, so any additions in that section cannot be compared.
- This comparison covers only the MD&A section text provided and does not reflect other sections or exhibits of either filing.
Risk Factors
- Added:
- Newer filing (2026-08-05) adds a new risk factor titled 'We may not be able to regain or maintain compliance with the continued listing standards of Nasdaq.'
- Newer filing (2026-08-05) adds disclosure that on July 29, 2026, Nasdaq notified the company that its common stock closing bid price had closed below $1.00 per share for 30 consecutive business days.
- Newer filing (2026-08-05) adds disclosure that the company has until January 25, 2027 to regain compliance with the Nasdaq Minimum Bid Price Requirement by maintaining a closing bid price of at least $1.00 per share for a minimum of ten consecutive business days.
- Newer filing (2026-08-05) adds a notice in the Risk Factors introductory paragraph stating 'Other than as described below, there have been no material changes to the risk factors described in that report.'
- Removed:
- Older filing (2026-05-06) states 'There have been no material changes to the risk factors described in that report.' without any exceptions; newer filing modifies this with the phrase 'Other than as described below.'
- Older filing (2026-05-06) includes disclosure under Item 2 about inducement stock options granted in Q1 2026 covering 120,000 shares with weighted average exercise price of $1.48 per share; newer filing (2026-08-05) states 'None' under Item 2.
- Reworded:
- In the Risk Factors introductory paragraph, the older filing (2026-05-06) states 'There have been no material changes to the risk factors described in that report.' The newer filing (2026-08-05) changes this to 'Other than as described below, there have been no material changes to the risk factors described in that report.'
- Under Item 5 'Other Information', the trading plans paragraph header 'Trading Plans' is present in the newer filing (2026-08-05) but not in the older filing (2026-05-06).
- Notes:
- The provided newer filing text is truncated at the end of Exhibit 3.3 and does not include the full exhibit list or signature page, so a complete comparison of Item 6 exhibits could not be performed.
- The provided older filing text includes Items 1A, 2, 3, 4, 5, and 6 as well as signatures; the newer filing text also includes these sections but is cut off mid-Item 6.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales are on record for CNTX — recent Form 4 activity was compensation-related (awards, option exercises, or tax withholding), not open-market buying or selling.
View full insider trading history → View SEC Form 3/4/5 filingsOnly open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding CNTX as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 8,661,347
- Reported value $4,797,522
reported quarterly holdings change (2026-03-31 → 2026-06-30): 1 new, 3 increased, 1 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about CNTX's institutional holders → See what each manager we track holds →
Short interest (FINRA)
CNTX had 6,907,157 shares of reported short interest as of the 2026-09-15 FINRA settlement date (delayed, bi-monthly; not real-time).
CNTX had 7.52% of its shares outstanding sold short as of the 2026-09-15 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 5.71 days to cover at the same settlement.
- Reported short interest (shares) 6,907,157
- Short interest (% of shares outstanding) 7.52%
- Prior settlement (shares) 6,466,057
- Reported change 6.82%
- Days to cover (reported) 5.71
Reported to FINRA as of the 2026-09-15 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- BioNTech (BNTX)
- Daiichi Sankyo (DSKY)
- TORL BioTherapeutics
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
CONTEXT THERAPEUTICS INC is found in…
Frequently asked questions
What does CONTEXT THERAPEUTICS INC (CNTX) do?
Context Therapeutics is a clinical-stage biopharmaceutical company focused on developing T cell engaging (TCE) bispecific antibodies to treat solid tumors. Its pipeline features candidates designed to redirect immune-mediated lysis toward specific tumor targets, with current lead programs targeting CLDN6 and Nectin-4. The company prioritizes developing novel therapeutic candidates through clinical-stage trials, either independently or through strategic partnerships.
What sector is CONTEXT THERAPEUTICS INC (CNTX) in?
CONTEXT THERAPEUTICS INC (CNTX) is classified in the Health Care sector. Its industry is Biotechnology. It trades on NASDAQ.
Who are CONTEXT THERAPEUTICS INC's (CNTX) competitors?
Notable peers of CONTEXT THERAPEUTICS INC (CNTX) include BioNTech, Daiichi Sankyo and TORL BioTherapeutics. This peer set is informational only — not financial advice.
Is CONTEXT THERAPEUTICS INC (CNTX) overbought or oversold right now?
CONTEXT THERAPEUTICS INC (CNTX) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 33, in the neutral middle (as of 2026-10-08). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on CNTX come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest; prices are market data, as of 2026-09-03; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.